Immunostimulants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.76, 1.10]< 115%10 studies (10/-)83.3 %some concernlow moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %some concernnot evaluable moderatecrucial-
deaths 0.93 [0.84, 1.03]< 122%28 studies (28/-)91.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.90 [0.63, 1.28]< 125%3 studies (3/-)72.4 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.75 [0.56, 1.01]< 14%5 studies (5/-)97.2 %some concernnot evaluable moderateimportant-
clinical improvement 1.15 [0.94, 1.40]> 140%10 studies (10/-)91.3 %some concerncritical moderateimportant-
clinical improvement (14-day) 3.00 [1.03, 8.75]> 117%2 studies (2/-)97.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.41 [0.86, 2.33]> 166%4 studies (4/-)91.3 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.86 [0.58, 1.28]> 10%2 studies (2/-)23.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.29 [1.00, 1.66]> 144%7 studies (7/-)97.4 %some concernserious moderateimportant-
death or ventilation 0.96 [0.88, 1.05]< 167%6 studies (6/-)79.6 %some concernnot evaluable moderateimportant-
hospital discharge 1.06 [0.95, 1.18]> 152%7 studies (7/-)85.1 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.92 [0.75, 1.13]< 17%10 studies (10/-)79.1 %some concernlow moderateimportant1
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %some concernnot evaluable moderateimportant-
viral clearance 3.95 [0.36, 43.59]> 194%3 studies (3/-)86.7 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 6.64 [0.42, 104.56]> 195%3 studies (3/-)90.9 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.10 [0.48, 2.49]> 142%2 studies (2/-)58.7 %some concernnot evaluable moderateimportant-
ICU admission 0.52 [0.33, 0.80]< 124%8 studies (8/-)99.8 %some concernserious moderatenon important-
recovery 1.40 [0.70, 2.80]> 166%2 studies (2/-)83.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %lownot evaluable highimportant-
serious adverse events 1.19 [1.02, 1.40]< 14%10 studies (10/-)1.4 %some concernlow moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-
adverse events 1.13 [0.92, 1.40]< 10%7 studies (7/-)12.4 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.